Endometrial	endometrial	O	O	OTHERS	I
carcinoma	carcinoma	O	DISEASE	OTHERS	I
after	after	O	O	O	O
Hodgkin	hodgkin	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
in	in	O	O	O	O
childhood	childhood	O	O	O	O
.	.	O	O	O	O

A	a	O	O	O	O
34-year-old	34-year-old	O	O	O	O
patient	patient	O	O	O	O
developed	developed	O	O	O	O
metastic	metastic	O	O	O	O
endometrial	endometrial	O	O	OTHERS	I
carcinoma	carcinoma	O	DISEASE	OTHERS	I
after	after	O	O	O	O
Hodgkin	hodgkin	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
in	in	O	O	O	O
childhood	childhood	O	O	O	O
.	.	O	O	O	O

She	she	O	O	O	O
had	had	O	O	O	O
ovarian	ovarian	O	O	OTHERS	I
failure	failure	O	O	OTHERS	I
after	after	O	O	O	O
abdominal	abdominal	O	O	O	O
irradiation	irradiation	O	O	O	O
and	and	O	O	O	O
chemotherapy	chemotherapy	O	O	O	O
for	for	O	O	O	O
Hodgkin	hodgkin	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
received	received	O	O	O	O
exogenous	exogenous	O	O	O	O
estrogens	estrogens	O	O	OTHERS	I
,	,	O	O	O	O
a	a	O	O	O	O
treatment	treatment	O	O	O	O
implicated	implicated	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
development	development	O	O	O	O
of	of	O	O	O	O
endometrial	endometrial	O	DISEASE	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
in	in	O	O	O	O
menopausal	menopausal	O	O	O	O
women	women	O	O	O	O
.	.	O	O	O	O

Young	young	O	O	O	O
women	women	O	O	O	O
on	on	O	O	O	O
replacement	replacement	O	O	O	O
estrogens	estrogens	O	O	OTHERS	I
for	for	O	O	O	O
ovarian	ovarian	O	O	OTHERS	I
failure	failure	O	O	OTHERS	I
after	after	O	O	O	O
cancer	cancer	O	DISEASE	OTHERS	I
therapy	therapy	O	O	O	O
may	may	O	O	O	O
also	also	O	O	O	O
have	have	O	O	O	O
increased	increased	O	O	O	O
risk	risk	O	O	O	O
of	of	O	O	O	O
endometrial	endometrial	O	O	OTHERS	I
carcinoma	carcinoma	O	DISEASE	OTHERS	I
and	and	O	O	O	O
should	should	O	O	O	O
be	be	O	O	O	O
examined	examined	O	O	O	O
periodically	periodically	O	O	O	O
.	.	O	O	O	O

